Eating

GLP-1 Medications List (2026): Every Approved Shot and Pill, What's Coming, and How They Differ

Jeff Zorn · · 6 min read

Share

By Jeff Zorn, founder of Zornava. Former college basketball player, degree in exercise science and nutrition, two years on GLP-1 medications. My experience, not medical advice. Talk to your prescriber or a registered dietitian about your own situation.

Published · Last reviewed

Short answer: as of November 13, 2026, the main GLP-1 medicines in the US are semaglutide (Ozempic, Wegovy injection, the Wegovy pill, Rybelsus and Ozempic tablets), tirzepatide (Mounjaro and Zepbound), which also acts on the GIP receptor, and orforglipron (Foundayo), a daily pill approved on April 1, 2026.[1][2][3] Retatrutide, nicknamed "GLP-3", is still in trials, with an FDA submission planned for early 2027.[4] Compounded copies are not FDA-approved.[5]

New to eating less? Start with what to eat when you're eating less, the guide the rest of Lighter Days builds on.

This page is the map. Each medicine has its own reference page built from its FDA label, and each of those links to what it costs, how it compares and what to eat on it. General information, not medical advice: which medicine, which dose and whether to switch are decisions for you and your prescriber.

Which GLP-1 medications are there?

Medicine Brands (maker) Receptors How it's taken US status, November 2026 Headline trial
Semaglutide Ozempic, Wegovy, Wegovy pill, Rybelsus, Ozempic tablets (Novo Nordisk) GLP-1 Weekly injection, or a daily tablet on an empty stomach Approved: type 2 diabetes (Ozempic, Rybelsus, Ozempic tablets); chronic weight management and heart risk (Wegovy injection and pill)[1] STEP 1: body weight −14.9% at 68 weeks on 2.4 mg, vs −2.4% on placebo[6]
Tirzepatide Mounjaro, Zepbound (Eli Lilly) GIP and GLP-1 Weekly injection (pen or vial) Approved: type 2 diabetes (Mounjaro, May 13, 2022); chronic weight management (Zepbound, November 8, 2023) and sleep apnea with obesity (December 20, 2024)[2] SURMOUNT-1: −20.9% at 72 weeks on 15 mg, vs −3.1% on placebo[7]
Orforglipron Foundayo (Eli Lilly) GLP-1 (a small molecule, not a peptide) Daily tablet, with or without food[8] Approved April 1, 2026 for chronic weight management; type 2 diabetes application under review[3] ATTAIN-1: −11.2% at 72 weeks on the top dose, vs −2.1% on placebo[9]
Retatrutide ("GLP-3") No brand (Eli Lilly) GIP, GLP-1 and glucagon Weekly injection in trials Not approved anywhere; FDA submission planned for Q1 2027[4] TRIUMPH-1: −25.0% at 80 weeks on 12 mg, vs −3.9% on placebo[10]
Compounded semaglutide or tirzepatide Pharmacy-made copies Same as the original, if made correctly Usually vials Not FDA-approved; legal only in narrow cases since the shortages ended[11] None for the compounded product itself

Results from different trials, populations and durations are not a head-to-head comparison. The one head-to-head trial so far, tirzepatide against semaglutide, is covered in Zepbound vs Wegovy.

How do they differ?

  • How many receptors. Semaglutide and orforglipron act on one receptor, GLP-1. Tirzepatide adds GIP, and retatrutide adds glucagon on top of both.[12][13][10]
  • Shot or pill. Ozempic, Wegovy, Mounjaro and Zepbound are weekly injections. The Wegovy pill, Rybelsus and Ozempic tablets are taken daily on an empty stomach with a small sip of water, then a wait of at least 30 minutes.[12][14] Foundayo's label says "with or without food".[8]
  • What they are approved for. The same molecule can carry different brand names for different uses: Ozempic and Mounjaro for type 2 diabetes, Wegovy and Zepbound for chronic weight management.[1][2]
  • Shared warnings. The injectable semaglutide and tirzepatide labels carry a boxed warning about thyroid C-cell tumors.[12][13] Each drug page lists its label's full warnings.

How do they compare, and what do they cost?

What about compounded versions?

Compounded semaglutide and tirzepatide spread while both were on the FDA shortage list. Tirzepatide came off in December 2024 and semaglutide in February 2025, and the grace periods for compounders ended by May 22, 2025.[11] The FDA does not check compounded drugs for safety, effectiveness or quality before they are sold.[5] The full story, including what is still legal, is on our compounded GLP-1 page.

What's coming next?

Retatrutide is the next large one: Lilly said on July 23, 2026 that it plans to submit it to the FDA in the first quarter of 2027.[4] Until then it is legal only inside trials and an expanded-access program, and the FDA warns against "research use" vials sold online.[15] We track it on what GLP-3 is, what its trials reported and what it might cost. This page is re-checked every month.

What do they all change about eating?

Whichever medicine it is, appetite gets smaller, and the 2025 joint advisory on nutrition with GLP-1 therapy puts protein first, with small, frequent, nutrient-dense meals and enough fluid, and names iron, calcium, vitamin D and B12 among the nutrients to watch.[16] Where to go next:

For transparency about why this page exists on our site: we make one product, Zornava Replenish, a lemon-lime daily hydration and nutrient powder for lighter appetite days, including for people on GLP-1 medications. It is a dietary supplement, not a medication, and it does not replace or imitate any medicine on this page. It is not on sale yet; early access opens February 9, 2027, and the early-access list is open now.

Frequently asked questions

What are the GLP-1 medications?

In the US as of November 2026: semaglutide (Ozempic, Wegovy injection, the Wegovy pill, Rybelsus, Ozempic tablets), tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo). Retatrutide is still in trials. Compounded copies are not FDA-approved.

Is there a GLP-1 pill?

Yes. The Wegovy pill (oral semaglutide 25 mg) was approved on December 22, 2025, and Foundayo (orforglipron) on April 1, 2026, both for chronic weight management. Rybelsus and Ozempic tablets are approved for type 2 diabetes. The semaglutide tablets are taken on an empty stomach; Foundayo's label says with or without food.

What is the difference between Ozempic and Wegovy?

Both are semaglutide from Novo Nordisk. Ozempic is approved for type 2 diabetes and Wegovy for chronic weight management and heart risk, at different label doses. The same is true of Mounjaro and Zepbound, which are both tirzepatide.

Is tirzepatide a GLP-1?

It is a dual agonist: it acts on the GLP-1 receptor and also on the GIP receptor. It is usually grouped with the GLP-1 medications.

Is GLP-3 a real drug class?

No. "GLP-3" is a nickname for retatrutide, which acts on three receptors: GIP, GLP-1 and glucagon. It is not approved anywhere as of November 13, 2026.

Are compounded GLP-1s legal?

Only in narrow cases since semaglutide and tirzepatide came off the FDA shortage list. Compounded drugs are not FDA-approved, and the FDA does not check their safety, effectiveness or quality before sale.

References

  1. US Food and Drug Administration. Drugs@FDA: Ozempic (NDA 209637), Rybelsus and Ozempic tablets (NDA 213051), Wegovy injection (NDA 215256) and Wegovy tablets (NDA 218316), approval history. Drugs@FDA. 2026. accessdata.fda.gov. Approval dates read from the Drugs@FDA submission records via openFDA (api.fda.gov/drug/drugsfda.json) and checked against the FDA approval letters for NDA 215256 S-005, S-023 and S-029, NDA 213051 S-020 and S-024, and NDA 218316 (original approval 2025-12-22). ↩︎
  2. US Food and Drug Administration. Drugs@FDA: Mounjaro (NDA 215866) and Zepbound (NDA 217806), approval history. Drugs@FDA. 2026. accessdata.fda.gov. Approval dates read from the Drugs@FDA submission records via openFDA and checked against the FDA approval letters for NDA 215866 S-039 (pediatric, 2025-12-19), S-044 and S-045 (2026-08-27), and NDA 217806 S-041 (2026-08-26). ↩︎
  3. US Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. fda.gov. 2026. fda.gov. Press announcement of 2026-04-01. ↩︎
  4. Eli Lilly and Company. Press release (PR Newswire, via BioSpace). 2026. biospace.com. Press release of 2026-07-23. Company-reported topline results; TRIUMPH-3 not yet in a journal as of 2026-11-13. ↩︎
  5. US Food and Drug Administration. Compounding and the FDA: Questions and Answers. fda.gov. 2025. fda.gov. Page read (content current as of 09/16/2025). ↩︎
  6. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. PubMed. PMID: 33567185. doi: 10.1056/nejmoa2032183. ↩︎
  7. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. PubMed. PMID: 35658024. doi: 10.1056/NEJMoa2206038. SURMOUNT-1. Abstract read. Funded by Eli Lilly. ↩︎
  8. Eli Lilly and Company. Foundayo (orforglipron) tablets, prescribing information. DailyMed, US National Library of Medicine. 2026. DailyMed. SPL read via DailyMed services (label effective 2026-07-29). ↩︎
  9. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796–1806. PubMed. PMID: 40960239. doi: 10.1056/NEJMoa2511774. ATTAIN-1. Abstract read (Europe PMC). Funded by Eli Lilly. ↩︎
  10. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026;395(18):1781–1793. PubMed. PMID: 42814954. doi: 10.1056/NEJMoa2604169. TRIUMPH-1. Abstract read. Funded by Eli Lilly. ↩︎
  11. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. fda.gov. 2026. fda.gov. Page read (content current as of 04/01/2026); dated entries from 2024-10-02 onward. ↩︎
  12. Novo Nordisk. Wegovy (semaglutide) injection and tablets, prescribing information and Medication Guide. DailyMed, US National Library of Medicine. 2026. DailyMed. ↩︎
  13. Eli Lilly and Company. Zepbound (tirzepatide) injection, prescribing information and Medication Guide. DailyMed, US National Library of Medicine. 2026. DailyMed. ↩︎
  14. Novo Nordisk. Rybelsus and Ozempic (semaglutide) tablets, prescribing information and Medication Guide. DailyMed, US National Library of Medicine. 2026. DailyMed. SPL read via DailyMed services (label effective 2026-01-30). ↩︎
  15. US Food and Drug Administration. fda.gov. 2026. fda.gov. Page read (content current as of 10/01/2026). ↩︎
  16. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475–1503. (sections on protein, meal pattern, fluids and nutrients of concern) Full text. PMID: 40445127. doi: 10.1002/oby.24336. ↩︎
Share this
← All Lighter Days articles

Free guide

The GLP-1 eating plan

Eight pages to print and keep, built protein first for days when appetite is small. Sourced, like everything on Lighter Days.

  • Seven days of four small meals, with protein and fiber counted
  • A food list: what to eat more often, and what to go easy on
  • A shopping list and a page to take to your prescriber or dietitian

You’ll also get early access to Replenish and a few emails a month. Unsubscribe any time.